The guidance cut is a clear negative surprise, but the company cites a single contract issue as 'temporary' and maintains revenue guidance. Watch the Q3 2026 earnings call for quantification of the EBITDA dollar impact and any signs of contagion to other payor contracts. The Investor Day today may provide strategic context but is unlikely to offset the near-term earnings disappointment.
Price Chart
Executive Summary
Auna pre-announced a material downgrade to its full-year 2026 Adjusted EBITDA guidance, now expecting consolidated Adjusted EBITDA to be 'broadly stable year over year' versus the prior guidance of 10%-14% FX-neutral growth. The revision is driven by unexpected cost pressure from a specific payor contract in Colombia due to a high incidence of advanced-stage cancer cases. Revenue growth guidance remains unchanged, and CapEx, free cash flow, and leverage trends are said to be evolving favorably.
Key Facts
- Full-year 2026 Adjusted EBITDA guidance lowered from 10%-14% FX-neutral growth to 'broadly stable year over year'.
- The revision is attributed to temporary cost pressure from a specific payor contract in Colombia with an unexpectedly high incidence of advanced-stage cancer cases.
- Full-year 2026 revenue growth guidance remains unchanged and 'in line' with prior guidance.
- Capital expenditure guidance maintained at approximately 4.0% of consolidated revenue.
- Company will host an Investor Day on October 22, 2026, and will provide further details on the Q3 2026 earnings call.
- The company is still completing its review of the payor contract's full-year impact on Adjusted EBITDA.
Financial Impact
Adjusted EBITDA growth guidance cut from 10%-14% FX-neutral to approximately 0% year-over-year growth — a swing of at least 10 percentage points of growth. Revenue guidance unchanged.
Risk Factors
- Further deterioration in the Colombia payor contract or similar issues in other markets.
- If the cost pressure persists beyond 2026, it could signal a structural problem in the Colombia book of business.
- The unchanged revenue guidance may also face risk if utilization trends soften.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0000950103-26-015991 |
| Document: dp255384_6k.htm | 0000950103-26-015991 |
| Document: 0000950103-26-015991-index-headers.html | 0000950103-26-015991 |
| Document: 0000950103-26-015991-index.html | 0000950103-26-015991 |
| Document: 0000950103-26-015991.txt | 0000950103-26-015991 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $5.03 $5.16 | ▼ −2.58% | ▼ −3.11% | $4.95 (+1.59%) |
Oct 8, 2026 19d ago | SC 13G/A | $5.10 $5.12 | ▲ +0.39% | ▼ −0.21% | $4.95 (−2.94%) |
Jul 15, 2026 14w ago | 6-K | $5.15 $5.12 | ▼ −0.58% | ▲ +0.41% | $4.95 (−3.88%) |
Jun 1, 2026 21w ago | Insider Cluster | $4.50 $4.48 | ▼ −0.44% | ▲ +0.28% | $4.95 (+10.00%) |
May 19, 2026 22w ago | 6-K | $4.38 $4.39 | ▲ +0.23% | ▲ +0.03% | $4.95 (+13.01%) |
Apr 22, 2026 26w ago | 6-K | $5.15 $5.20 | ▲ +0.97% | ▲ +0.19% | $4.95 (−3.88%) |
Apr 22, 2026 26w ago | 20-F | $5.21 $5.15 | ▼ −1.15% | ▼ −0.76% | $4.95 (−4.99%) |
Apr 17, 2026 27w ago | 6-K | $5.62 $5.52 | ▼ −1.78% | ▼ −1.59% | $4.95 (−11.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers